RAINFO LEXICON
Abbreviations and Acronyms
NOTE: This is a work-in-progress.
Send additions and corrections to the webmaster.
|
120-day Safety Report |
Amendment to a NDA due 120 days after the NDA is filed that contains a safety update. |
|
30-day hold |
Time period between filing a protocol under an IND and FDA OK to proceed with enrollment. |
|
510(k) |
Premarket Notification Submission (United States) |
|
510(k) |
A premarket notification submitted to FDA to demonstrate that the medical device to be marketed is as safe and effective or substantially equivalent to a legally marketed device. 510(k) refers to the section of the FD&C Act authorizing the submission of the premarket notification. |
|
510K |
Premarket Notification Submission (United States) |
|
AAA |
Abdominal Aortic Aneurysm |
|
AAAS |
American Association for the Advancement of Science |
|
AABB |
American Association of Blood Banks |
|
AACC |
American Association for Clinical Chemistry (United States) |
|
AADA |
Abbreviated Antibiotic Drug Application (primarily used for generics) |
|
AAHP |
American Association of Health Plans (United States) |
|
AAMI |
Association for the Advancement of Medical Instrumentation (United States) |
|
AAPS |
American Association of Pharmaceutical Scientists |
|
Abbreviated 510(k) |
submission based on guidance document(s); special controls or standards. |
|
ABHI |
Association of British Health Care Industries (United Kingdom) |
|
ABIMO |
Medical device trade association (Brazil) |
|
ABPI |
Association of the British Pharmaceutical Industry (United Kingdom) |
|
ACC |
American College of Cardiology (United States) |
|
ACE |
Adverse Clinical Event |
|
ACGIH |
American Conference of Governmental Industrial Hygienists (United States) |
|
ACII |
American Standard Code for Information Exchange (United States) |
|
ACNP |
American College of Nuclear Physicians (United States) |
|
ACR |
American College of Radiology (United States) |
|
ACRP |
American Clinical Research Professionals (United States) |
|
ACS |
American Chemical Society |
|
Action Letter |
Official communication of FDA informing NDA sponsor of an agency decision. Includes approvable, not approvable, clinical hold and warning letters. |
|
Active Ingredient |
Any drug component that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body of man or other animals. |
|
ADA |
American Dental Association (United States) |
|
ADA |
Americans with Disabilities Act (United States) |
|
ADDM |
Association of Disposable Device Manufacturers |
|
ADE |
Adverse Drug Event, or Adverse Drug Experience |
|
ADME |
Absorption, distribution, metabolism, and elimination (of a drug) |
|
ADME |
Absorption, Distribution, Metabolism, and Excretion |
|
ADP |
Automated Data Processing |
|
ADR |
Adverse Drug Reaction |
|
ADR |
Adverse Drug Reaction |
|
ADRAC |
(Australia) |
|
Adulterated |
Product is not made according to GMPs or is contaminated. |
|
AE |
Adverse Event |
|
AER |
Adverse Event Report |
|
AERS |
Adverse Events Reporting System |
|
AERS |
Adverse Event Reporting System |
|
AESGP |
An OTC industry association in Europe |
|
AETSA |
Agencia de Evaluación de Tecnologias Sanitarias de Andalucia (Spain) |
|
AFDO |
Association of Food and Drug Officials |
|
AFSSAPS |
Agence Française de Sécurité Sanitaire des Produits de Santé (France) |
|
AGIM |
Belgian industry association (pharmaceuticals) |
|
AGRD |
(Australia) |
|
AGRF |
Australian Genome Research Facility |
|
AHCPR |
Agency for Health Care Policy and Research |
|
AHCPR |
Agency for Health Care Policy and Research (obsolete, use AHRQ) |
|
AHRQ |
Agency for Healthcare Research and Quality (pronounced “arc”) |
|
AIC |
Adverse Incident Centre (United Kingdom - MDA) |
|
AIDS |
Acquired Immune Deficiency Syndrome |
|
AIMD |
Active Implantable Medical Device |
|
AIMDD |
Active Implantable Medical Device Directive
|
|
AIP |
Application Integrity Policy: the policy contains the agency’s approach regarding the review of applications that may be affected by wrongful acts that raise significant questions regarding data reliability. |
|
AIUM |
American Institute of Ultrasound in Medicine (United States) |
|
AMA |
American Medical Association |
|
AMDM |
Association of Medical Device Manufacturers (Hungary) |
|
AMDR |
Association of Medical Device Reprocessors |
|
Amendment |
Additions or changes to a NDA, PMA or PMA supplement still under review. Includes safety updates. |
|
ANADA |
Abbreviated New Animal Drug Application (United States) |
|
ANADA |
Abbreviated New Animal Drug Application |
|
ANAES |
Medical technology evaluation agency (France) |
|
ANDA |
Abbreviated New Drug Application (United States- FDA) |
|
ANDA |
Abbreviated New Drug Application (used for generic drugs) |
|
ANIMAT |
Administración Nacional de Medicamentos, Alimentos y Tecnologia Médica (Argentina) http://www.anmat.gov.ar/principal.html |
|
ANMV |
French national veterinary medicines agency |
|
Annual report |
An annual report to an active IND is required. Summaries of preclinical and clinical investigations, safety reports not previously filed and updates to CMC information are included. Report to be submitted by manufacturers of radiation emitting devices. Report to be submitted by sponsors of IDEs to IRBs and FDA (also called Progress Report). |
|
ANOM |
Analysis of Means |
|
ANOVA |
Analysis of Variance |
|
ANPR |
Advance Notice of Proposed Rulemaking (United States) |
|
ANSI |
American National Standards Institute (United States) |
|
ANVS |
Agencia
Nacional de Vigilancia Sanitaria (National Agency of Health
Surveillance) |
|
APA |
American Psychiatric Association (United States) |
|
APA |
American Pharmaceutical Association |
|
APB |
Pharmacist's association (Belgium) |
|
APhA |
American Pharmaceutical Association |
|
APHIS |
Animal and Plant Health Inspection Service |
|
API |
Application Program Interface |
|
API |
Active Pharmaceutical Ingredient |
|
API |
Active Pharmaceutical Ingredient |
|
APIFARMA |
Portugal |
|
Approved |
FDA designation given to drugs, biologics and medical devices that have approved marketing applications (NDA, BLA or PMA). |
|
AQL |
Acceptable Quality Level |
|
ARC |
AIDS Related Complex |
|
ARC |
American Red Cross (United States) |
|
ARTG |
Australian Register of Therapeutic Goods |
|
ASA |
Acoustical Society of America (United States) |
|
ASM |
American Society for Microbiology |
|
ASME |
American Society of mechanical Engineers (United States) |
|
ASQ |
American Society for Quality (formerly ASQC) |
|
ASR |
Analyte Specific Reagent (United States - FDA) |
|
ASTM |
American Society for Testing and Materials (United States) |
|
ATCC |
American Type Culture Collection (United States) |
|
ATF |
Bureau of Alcohol, Tobacco and Firearms |
|
AUA |
Authorised User Access (Australia) |
|
AUC |
Area Under the Curve |
|
AUST L |
Numbering scheme for Australian conformity mark |
|
AUST R |
Numbering scheme for Australian conformity mark |
|
AV |
Atrioventricular |
|
B/F |
Bacteriostasis/Fungistasis (USP) |
|
BACPAC |
Bulk Activities Post Approval Changes (United States - FDA) |
|
BACPAC |
Bulk Actives Post Approval Changes |
|
BAH |
German medicines manufacturers association |
|
BAH |
OTC association (Germany) |
|
Banned Device |
A device that presents a substantial deception, unreasonable risk of injury or illness, or unreasonable direct and substantial danger to the public health. |
|
BEI |
Biological Exposure Indicies |
|
BfArM |
Federal Institute for Drugs and Medical Devices (Germany) http://www.bfarm.de/gb_ver/ |
|
BHF |
Batch History File |
|
BHR |
Batch History Record |
|
BiMo |
Bioresearch Monitoring (United States - FDA) |
|
BIO |
Biotechnology Industry Organization |
|
Biologic |
Any virus, therapeutic serum, toxin, antitoxin, or analogous product applicable to the prevention, treatment or cure of diseases or injuries in man. |
|
BIRA |
British Institute of Regulatory Affairs |
|
BL |
Biologics License (United States) |
|
BLA |
Biologics License Application (United States - FDA) |
|
BLA |
Biologics License Application (replaces PLA/ELA) |
|
Blinded Study |
Clinical trial where the patient (single-blind) or patient and investigator (double-blind) are unaware of which treatment the patient receives. Involves use of multiple treatment groups such as other active, placebo or alternate dose groups. Sometimes termed “Masked.” |
|
BMA |
British Medical Association (UK) |
|
BMJ |
British Medical Journal (UK) |
|
BPI |
German industry association of small- and medium-sized pharmaceutical companies in Germany |
|
BSE |
Bovine Spongiform Encephalopathy |
|
BVmed |
German medical device industry association http://www.bvmed.de |
|
CA |
Certification Authority |
|
CA |
Competent Authority |
|
CA |
Competent Authority Governmental agency in each EC member state responsible for monitoring and enforcing the MDD. |
|
CAB |
Conformity Assessment Body |
|
CAB |
Conformity Assessment Body (EU) |
|
CABG |
Coronary Artery Bypass Graft |
|
CAD |
Computer Aided Design |
|
CADREAC |
Collaboration Agreement of Drug Regulatory Authorities of EU-associated Countries |
|
CAE |
|
|
CAM |
|
|
CANDA |
Computer Assisted New Drug Application (obsolete) |
|
CANDA |
Computer Aided New Drug Application (United States) |
|
CAP |
College of American Pathologists (United States) |
|
CAPA |
Corrective and Preventive Actions |
|
CAPLA |
Computer Assisted Product License Application (obsolete) |
|
CAPLA |
Computer Aided Product License Application (United States) |